Results 201 to 210 of about 21,695 (218)
Some of the next articles are maybe not open access.
Drug-Eluting Balloons to Treat Iliac In-Stent Restenosis
Annals of Vascular Surgery, 2015To report our experience in the use of drug-eluting balloons (DEBs) for the treatment of symptomatic iliac in-stent restenosis (ISR).Six patients underwent treatment using DEBs for iliac ISRs in our centers between September 2011 and May 2014. The patients were predominantly women (4 of 6, 66.7%) with a mean age of 67.2 years (range, 46-75 years ...
Troisi N. +6 more
openaire +2 more sources
Drug-eluting balloons: future potential indications and applications
EuroIntervention, 2011The drug-eluting balloon (DEB) is an exciting new technology that holds much promise. As an evolving technology undergoing intensive research, the device is being constantly refined and its numerous potential applications studied. Though initially created to fulfil specific needs in the coronary vasculature, there is great potential for its use in ...
openaire +2 more sources
Catheterization and Cardiovascular Interventions, 2020
Key Points Previous meta‐analysis raised concerns about the safety of paclitaxel‐coated devices in the treatment of PAD. However, real world data does not seem to agree with these findings. Increased mortality in patients with peripheral arterial disease and the true and beneficial treatment effects of these technologies need to be clarified as many ...
Kılıç, İsmail Doğu +1 more
openaire +2 more sources
Key Points Previous meta‐analysis raised concerns about the safety of paclitaxel‐coated devices in the treatment of PAD. However, real world data does not seem to agree with these findings. Increased mortality in patients with peripheral arterial disease and the true and beneficial treatment effects of these technologies need to be clarified as many ...
Kılıç, İsmail Doğu +1 more
openaire +2 more sources
Drug eluting balloons for resistant arteriovenous dialysis access stenosis
The Journal of Vascular Access, 2017Vascular access maintenance is vital for hemodialysis patients. Conventional balloon angioplasty is the gold standard of treatment in endovascular therapy according to published guidelines, accompanied by bare metal stents as a bail-out method. Several devices have been used so far with a view to improve patency outcomes, but only covered stents have ...
Dimitrios, Karnabatidis +1 more
openaire +2 more sources
Late catch-up phenomenon after drug-eluting balloon angioplasty
International Journal of Cardiology, 2013First generation DIOR (Eurocor, Bonn, Germany) was used in 69% of patients whereas second generation DIOR was used in the remaining subjects. The first generation DIOR consisted in a three-folded balloon with a microporous surface on which paclitaxel was dissolved at a concentration of 3 μg/mm 2 .
Gregory A, Sgueglia +2 more
openaire +2 more sources
Drug-eluting balloons for percutaneous coronary interventions
Thrombosis and Haemostasis, 2009Correspondence to: Marco Zimarino, MD, PhD Institute of Cardiology “G. d’Annunzio” University – Chieti C/o Ospedale SS. Annunziata Via dei Vestini, 66013 Chieti, Italy Tel: +39 0871 41512, Fax: +39 0871 402817 E-mail: m.zimarino@unich.it Received: November 27, 2008 Accepted: November 27, 2008 Prepublished online: December 4, 2008 doi:10.1160/TH08-11 ...
Zimarino M, De Caterina R
openaire +3 more sources
Advances in below-the-knee drug-eluting balloons.
The Journal of cardiovascular surgery, 2012The management of critical limb ischemia due to below-the-knee disease remains challenging due to the frequent patient comorbidities, diffuse vascular involvement, and high rates of restenosis and disease progression. The BASIL study has established the substantial equivalence between bypass surgery and percutaneous transluminal angioplasty in this ...
R. Ferraresi +2 more
openaire +2 more sources
Catheterization and Cardiovascular Interventions, 2012
AbstractThe management of in‐stent restenosis (ISR) complicating bifurcation lesions is technically challenging and implant of further stents may not be feasible. The use of drug‐eluting balloons provides an attractive option for treatment of such lesions allowing a technically simple procedure without the need for further complex stenting. The SeQuent
Yogesh, Raja +2 more
openaire +2 more sources
AbstractThe management of in‐stent restenosis (ISR) complicating bifurcation lesions is technically challenging and implant of further stents may not be feasible. The use of drug‐eluting balloons provides an attractive option for treatment of such lesions allowing a technically simple procedure without the need for further complex stenting. The SeQuent
Yogesh, Raja +2 more
openaire +2 more sources
Drug-eluting balloon: Very short-term exposure and overlapping
Thrombosis and Haemostasis, 2009SummaryPaclitaxel balloon coating has shown promising effects in inhibiting restenosis in initial clinical trials. The aim of the present study was to evaluate the influence of two critical features of drug-eluting balloon (DEB) application – inflation time and increased dose due to overlapping balloons.
Bodo, Cremers +6 more
openaire +2 more sources
Drug-Eluting Balloons in Coronary Bifurcation Lesions
2019The use of drug-eluting stents (DES) has reduced restenosis after percutaneous coronary intervention (PCI) by mechanically preventing vessel wall recoil and late negative remodeling and by pharmacologically inhibiting neointimal hyperplasia [1]. However complex lesions, such as bifurcation lesions, which account for 15–20% of all lesions treated ...
Anouar Belkacemi, Pieter R. Stella
openaire +1 more source